Chemotherapy News and Research

Latest Chemotherapy News and Research

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Study reveals how MMSET gene enables disease-causing mutations to occur

For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn't been clear, however, is how the body's genome sustains such destructive glitches in the first place.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

Study finds recurrences of shingles prevalent in the immunocompetent population

For decades, medical wisdom about shingles has been that it's a once-in-a-lifetime experience. The commonly-held belief is that patients are protected from a recurrence of the herpes zoster virus, which causes shingles, after one episode. But according to a study published in the February issue of Mayo Clinic Proceedings, recurrences of shingles may be significantly more common than doctors have suspected.

2 Feb 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."

2 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

$Researchers find breast cancer therapy contributes to early-in-life hip fractures in women$

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

A hip fracture is not common in a 54-year-old woman, unless she is a 54-year-old breast cancer survivor, according to a new Northwestern Medicine study. Researchers found that a combination of early menopause due to breast cancer treatment and common drugs used to treat breast cancer, could be weakening the bones of breast cancer survivors once they hit middle age, leading to hip fractures.

2 Feb 2011

Study finds treatment-related mortality with bevacizumab in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab may be at an increased risk of treatment-related death when the drug is used in combination with other therapies.

2 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Oncology experts to discuss latest developments in head and neck cancers

The European Society for Therapeutic Radiology and Oncology (ESTRO), the European Head and Neck Society (EHNS), and the European Society for Medical Oncology (ESMO) in collaboration with other European partners, have the pleasure of inviting you to report on the 3rd International Conference on innovative approaches In Head and Neck Oncology that will be held in Barcelona (Spain) on the 24th -26th February 2011.

1 Feb 2011

Roundup: Tenn. community health centers feel budget pinch; Minn. faces struggles with costs of inmate care

Originally created to care for destitute urban dwellers or dirt-poor sharecroppers, health centers today serve a much wider segment of America. A prolonged recession and a shortage of primary care physicians have expanded their patient base. Going forward, they are expected to meet the needs of millions more Americans. But getting there could be a challenge.

1 Feb 2011

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.

1 Feb 2011

Research on triple negative disease can benefit patients with breat cancer

Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

1 Feb 2011

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

High levels of circulating DNA may indicate faster progression of lung cancer and lower overall survival, according to a study published in the February edition of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

1 Feb 2011

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration has approved its Renegade HI-FLO Fathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature.

1 Feb 2011

Researchers to develop computer-assisted diagnosis tools for pathologists

Researchers are leveraging Ohio Supercomputer Center resources to develop computer-assisted diagnosis tools that will provide pathologists grading Follicular Lymphoma samples with quicker, more consistently accurate diagnoses.

31 Jan 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Losartan improves effectiveness of nanotherapeutics against cancer

Study reveals how MMSET gene enables disease-causing mutations to occur

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

Study finds recurrences of shingles prevalent in the immunocompetent population

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Researchers find breast cancer therapy contributes to early-in-life hip fractures in women

Study finds treatment-related mortality with bevacizumab in cancer patients

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Oncology experts to discuss latest developments in head and neck cancers

Roundup: Tenn. community health centers feel budget pinch; Minn. faces struggles with costs of inmate care

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Research on triple negative disease can benefit patients with breat cancer

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Researchers to develop computer-assisted diagnosis tools for pathologists

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in